en · de · es · pt
analytical-notes.peptides4088.com › Info › Mechanism And Regulatory Status — Evidence Review

Mechanism And Regulatory Status — Evidence Review

By Editorial Desk · published 2025-12-13 · last reviewed 2026-01-03 · Info

The short version of hGH fragment fits in a sentence. The long version — which is the one that helps — is below.

This page was last updated on 2026-01-03 and is reviewed periodically as new material appears.

Mechanism and Regulatory Status

Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.

Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.

Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.

Background and Development History

Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.

Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.

AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.

Aod-9604 at a glance

PropertyValueNotes
Typical storage temperature-20 °CLyophilized peptide; protect from moisture and light.
Typical analytical methodHPLC and mass spectrometryUsed to confirm identity and estimate purity.
Common synonymsAOD9604; hGH 176-191Naming varies by supplier and publication.
Disulfide bondsOneAffects folded structure and stability.
Typical research purity≥95%Value depends on supplier and analytical method.

Regulation and Detection Context

Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.

AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.

Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.

Related pages on this site

Background And Research Context

The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.

In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.

Further detail

=== Blood thinners === The trend in skin surgery over the last 10 years has been to continue anticoagulants while performing skin surgery. Most cutaneous bleeding can be controlled with electrocautery, especially bipolar forceps. The benefit gained by ease of hemostasis is weighed against the risk of stopping anticoagulants; and it is generally preferred to continue anticoagulants.

=== Pests === Common herbarium pests include: silverfish, book lice (psocids), cigarette or tobacco beetles (Lasioderma), dermestids, drugstore beetles (Stegobium paniceum) A reoccurring threat to the longevity of herbarium specimens is insects, a number of which find dried plants palatable. Historically, various methods have been used to kill insects, which either come in with the plants when they are collected or are in the building where the plants are stored. Pests are commonly treated with two different methods:

13 December Mark Drakeford resigns as First minister of Wales after five years in incumbent. Bernard Looney, the former chief executive of BP, is to forfeit up to £32.4m in salary and benefits after an investigation found he committed "serious misconduct" in failing to disclose relationships with colleagues. 14 December The Bank of England keeps interest rates on hold for a third consecutive time at 5.25%. 17-year-old Alex Batty, a boy from Oldham who went missing in 2017 while on holiday in Spain, is reported by French Police to have been found at Revel, a town east of Toulouse in France. Three men are convicted of attempted murder after two children (including an 11-year-old girl) were shot while playing on a climbing frame, in Wolverhampton. Panini Group launches the first sticker album for the Women's Super League. 15 December The High Court rules that Prince Harry was the victim of phone hacking by Mirror Group Newspapers and awards him £140,600 in damages. Separately, the judge rules that Piers Morgan knew about phone hacking – and was involved – while editor of the Daily Mirror. Muslim convert Edward Little, who planned to kill a Christian preacher at Speaker's Corner in London's Hyde Park, is sentenced to life imprisonment with a minimum term of 16 years following a trial at the Old Bailey. Network Rail regional manager Michelle Handforth resigns from her post following a power outage at Ladbroke Grove earlier in the month which left hundreds of train passengers stranded for several hours.

1952: American computer scientist Grace Hopper completed what is considered to be the first compiler, a program that allows a computer user to use a human-readable high-level programming language instead of machine code. It was known as the A-0 compiler. 1952: Photograph 51, an X-ray diffraction image of crystallized DNA, was taken by Raymond Gosling in May 1952, working as a PhD student under the supervision of British chemist and biophysicist Rosalind Franklin; it was critical evidence in identifying the structure of DNA. 1952: Canadian agriculturalist Mary MacArthur became the first female Fellow of the Agricultural Institute of Canada for her contributions to the science of food dehydration and freezing. 1952: American physician, obstetrical anesthesiologist and medical researcher Virginia Apgar devised the Apgar score, a way to quickly assess the health of a new-born child immediately after birth in order to combat infant mortality. 1953: Canadian-British radiobiologist Alma Howard co-authored a paper proposing that cellular life transitions through four distinct periods. This became the first concept of the cell cycle. 1954: New Zealand botanist Lucy Cranwell was the first female recipient of the Hector Medal from the Royal Society of New Zealand. She was recognized for her pioneering work with pollen in the emerging field of palynology. 1955: Scottish-Canadian Arctic ice researcher Moira Dunbar became the first female glaciologist to study sea ice from a Canadian icebreaker ship.

Sources: en.wikipedia.org

Background from the literature

== Diagnosis == Kwashiorkor, or edematous malnutrition, like many other malnutrition diseases, is indirectly assessed using anthropometry. Kwashiorkor is a subtype of severe acute malnutrition (SAM) characterized by bilateral peripheral pitting edema. According to the World Health Organization, the SAM diagnosis parameters are a "mid-upper arm circumference (MUAC) of < 115 mm, weight-for-height/length Z-score (WHZ) of < -3Z and nutritional edema or any combination of these parameters." Additional clinical findings on physical exam include marked muscle atrophy, abdominal distension, dermatitis, and hepatomegaly. WHO criteria for clinical assessment of malnutrition are based on the degree of wasting (MUAC), stunting (weight-for-height Z-score), and the presence of edema (mild to severe). In addition to anthropometric measures, laboratory tests can be critical for diagnosing kwashiorkor. Low serum albumin levels (hypoalbuminemia) are a hallmark of protein deficiency, and elevated liver enzymes may indicate liver dysfunction. Electrolyte imbalances and blood tests may also be used to assess the degree of organ involvement and complications. Specifically in children, severe malnutrition, such as kwashiorkor, can lead to notable changes in brain function and behavior. Children with kwashiorkor tend to be irritable and may develop cerebral atrophy, whereas those with severe wasting frequently show apathy, reduced movement, and speech delays. These neurological and behavioral changes are key factors in the clinical assessment of malnutrition.

After extensive testing, which can take up to six years, the new medicine is ready for marketing and selling. Because of these long timescales and the fact that only one out of every 5000 potential new medicines will ever reach the open market, this is an expensive way of doing things, often costing over 1 USD billion per drug. To recoup this outlay, pharmaceutical companies may do a number of things:

== Spectrum == The mass spectrum of the secondary ions emitted from the bombarded surface during SSIMS provides direct information of not only the chemical composition but also of the chemical structure of the bombarded area. This is because the mass spectrum includes cluster ions as well as elemental ions. These cluster ions reflect the surface chemistry in a detailed way. The figure shows the mass spectrum obtained from a SSIMS analysis of polytetrafluoroethylene (PTFE). The positive ion spectrum shows positive atomic ions (i.e. C+) and molecular ions (i.e. CF+, CF3+, C3F3+) of the target. The negative ion spectrum shows negative atomic ions (i.e. F−) and molecular ions (i.e. F2−, CF3−, C3F3−).

== Manufacturing == Manufacturing of mRNA vaccines can be performed rapidly in high volume, including use of portable, automated printers ("RNA microfactories") for which CureVac has a joint development partnership with Tesla. mRNA vaccines require stringent cold chain refrigeration throughout manufacturing, distribution and storage. The CureVac technology for CVnCoV uses a non-modified, more natural mRNA less affected by hydrolysis, enabling storage at 5 °C (41 °F) and relatively simplified cold chain requirements that facilitate up to three months of storage and distribution to world regions that do not have specialized ultracold equipment. CureVac had a European-based network to accelerate manufacturing of CVnCoV, if proven safe and effective, for production of up to 300 million doses in 2021 and 600 million doses in 2022. An estimated 405 million doses would have been provided to EU states.

India's population was 361 million in 1951. It grew to approximately 1.464 billion in 2025, surpassing China's population in 2021. 1,210,193,422 residents were reported in the 2011 provisional census report. The median age was 28.7 in 2020. Medical advances made in the last 50 years as well as increased agricultural productivity brought about by the "Green Revolution" have caused India's population to grow rapidly, though India's decennial rates of growth are decreasing: its population grew by 17.64% from 2001 to 2011, compared to 21.54% growth in the previous decade (1991–2001). The first post-colonial census, conducted in 1951, counted 361 million people. The life expectancy at birth has increased from 49.7 years in 1970–1975 to 72.0 years in 2023. The under-five mortality rate for the country was 113 per 1,000 live births in 1994, and had declined to 41.1 per 1,000 live births by 2018. The 2011 census reported a human sex ratio of 940 females per 1,000 males. Female infanticide in India, and lately female foeticide, have created lopsided gender ratios; the number of missing women in the country quadrupled from 15 million to 63 million during the period 1964–2014, faster than the population growth during the same period. According to an Indian government study, an additional 21 million girls are unwanted and do not receive adequate care. Despite a government ban on sex-selective foeticide, the practice persists. Migration from rural to urban areas has been an important dynamic in India's recent history.

Sources: en.wikipedia.org

Reference notes

Moreover, each viewpoint substantially uses the same foundational concepts (defined in Part 2 of RM-ODP). However, the viewpoints are sufficiently independent to simplify reasoning about the complete specification. The mutual consistency among the viewpoints is ensured by the architecture defined by RM-ODP, and the use of a common object model provides the glue that binds them all together. More specifically, the RM-ODP framework provides five generic and complementary viewpoints on the system and its environment:

== History of the field == An early time-of-flight mass spectrometer, named the Velocitron, was reported by A. E. Cameron and D. F. Eggers Jr, working at the Y-12 National Security Complex, in 1948. The idea had been proposed two years earlier, in 1946, by W. E. Stephens of the University of Pennsylvania in a Friday afternoon session of a meeting, at the Massachusetts Institute of Technology, of the American Physical Society. In 1953, Stephens reported an improved design that could resolve the cyclic hydrocarbons up to cycloheptane using an instrument constructed at the Esso Laboratories, reporting that the main limitations were "primarily in sensitivity and outgassing of the ion source." By 1955, compounds with masses over 100 g/mol could be resolved.

The first refrigerator to see widespread use was the General Electric "Monitor-Top" refrigerator introduced in 1927, so-called, by the public, because of its resemblance to the gun turret on the ironclad warship USS Monitor of the 1860s. The compressor assembly, which emitted a great deal of heat, was placed above the cabinet, and enclosed by a decorative ring. Over a million units were produced. As the refrigerating medium, these refrigerators used either sulfur dioxide, which is corrosive to the eyes and may cause loss of vision, painful skin burns and lesions, or methyl formate, which is highly flammable, harmful to the eyes, and toxic if inhaled or ingested. The introduction of Freon in the 1920s expanded the refrigerator market during the 1930s and provided a safer, low-toxicity alternative to previously used refrigerants. Separate freezers became common during the 1940s; the term for the unit, popular at the time, was deep freeze. These devices, or appliances, did not go into mass production for use in the home until after World War II. The 1950s and 1960s saw technical advances like automatic defrosting and automatic ice making. More efficient refrigerators were developed in the 1970s and 1980s, even though environmental issues led to the banning of very effective (Freon) refrigerants. Early refrigerator models (from 1916) had a cold compartment for ice cube trays.

=== Operation Enduring Freedom – Horn of Africa === During December 2002 and January 2003, Special Operation Detachment – Central (SOD-C) arrived to augment Joint Special Operations Task Force – Horn of Africa (JSOTF-HOA). The SOD concept was new and consisted of experienced National Guard Special Forces Officers and NCOs who served as the JSOTF's core staff. Besides the SOD-C, JSOTF-HOA included Air Force Special Operations Detachment-Alpha (AFSOD-A), an SF detachment, a SEAL platoon, and a Naval Special Warfare (NSW) rigid inflatable boat (RIB) detachment. In November 2006, 20th SFG Headquarters deployed to round out the Special Operations Command and Control Element – Horn of Africa (SOCCE-HOA) staff for two years. This initiative allowed SOCCE-HOA to better accomplish its missions. American Special Forces carried out operations in support of Ethiopian troops during the invasion of Somalia in December 2006 aimed at toppling the Islamic Courts Union.

Sources: en.wikipedia.org

Frequently asked questions

Is AOD-9604 approved for weight loss?

No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.

Why is AOD-9604 banned in sports?

The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.

Does AOD-9604 raise growth hormone levels?

It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.

What is AOD9604 derived from?

AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.

Network